Exelixis takes $20m option Iconic/Zymeworks’ cancer ADCExelixis has taken a $20 million option to license in an antibody-drug conjugate cancer (ADC) drug from Iconic, Share XExelixis takes $20m option Iconic/Zymeworks’ cancer ADChttps://pharmaphorum.com/news/exelixis-takes-20m-option-iconic-zymeworks-cancer-adc/
